Amplify Weight Loss Drug & Treatment ETF
  
Schedule of Investments
  
December 31, 2024 (Unaudited)
  
   
COMMON STOCKS - 98.5%
  
Shares
    
Value
 
Health Care - 91.1%(a)
        
Altimmune, Inc. (b)
    
1,348
    
$
9,719
  
Amgen, Inc.
    
747
      
194,698
  
AstraZeneca PLC - ADR
    
2,957
      
193,743
  
Bachem Holding AG
    
249
      
15,908
  
Chugai Pharmaceutical Co. Ltd.
    
4,900
      
218,218
  
Eli Lilly & Co.
    
839
      
647,708
  
Gerresheimer AG
    
263
      
19,336
  
Gubra AS (b)
    
59
      
5,112
  
Hanmi Pharm Co. Ltd.
    
119
      
22,674
  
Hims & Hers Health, Inc. (b)
    
1,386
      
33,513
  
Innovent Biologics, Inc. (b)(c)
    
28,500
      
134,283
  
Merck & Co., Inc.
    
1,964
      
195,379
  
Merck KGaA
    
1,013
      
146,749
  
Novo Nordisk AS - ADR
    
6,037
      
519,303
  
OPKO Health, Inc. (b)
    
6,098
      
8,964
  
Pfizer, Inc.
    
8,613
      
228,503
  
Roche Holding AG
    
697
      
196,506
  
Structure Therapeutics, Inc. - ADR (b)
    
3,107
      
84,262
  
Terns Pharmaceuticals, Inc. (b)
    
1,188
      
6,582
  
Teva Pharmaceutical Industries Ltd. - ADR (b)
    
8,880
      
195,715
  
Thermo Fisher Scientific, Inc.
    
417
      
216,936
  
United Laboratories International Holdings Ltd.
    
8,000
      
12,729
  
Viking Therapeutics, Inc. (b)
    
2,066
      
83,136
  
West Pharmaceutical Services, Inc.
    
564
      
184,744
  
Ypsomed Holding AG
    
30
      
10,841
  
Zealand Pharma AS (b)
    
1,217
      
120,912
  
             
3,706,173
  
                 
Information Technology - 4.3%
          
FUJIFILM Holdings Corp.
    
8,300
      
174,756
  
                 
Materials - 3.1%
          
Mitsubishi Chemical Group Corp.
    
24,600
      
125,176
  
TOTAL COMMON STOCKS (Cost $4,579,957)
      
4,006,105
  
                 
SHORT-TERM INVESTMENTS - 2.0%
                
Money Market Funds - 2.0%
                
Invesco Government & Agency Portfolio – Institutional Class, 4.42% (d)
    
83,307
      
83,307
  
TOTAL SHORT-TERM INVESTMENTS (Cost $83,307)
      
83,307
  
                 
TOTAL INVESTMENTS - 100.5% (Cost $4,663,264)
      
4,089,412
  
Liabilities in Excess of Other Assets - (0.5)%
      
(21,280
)
TOTAL NET ASSETS - 100.0%
          
$
4,068,132
  
two
      
–
%
Percentages are stated as a percent of net assets.
      
–
%
   
The Global Industry Classification Standard ("GICS®") was developed by and/or is the exclusive property of MSCI, Inc. ("MSCI") and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.
  

ADR - American Depositary Receipt
AG - Aktiengesellschaft
AS - Aksjeselskap
KGaA - Kommanditgesellschaft auf Aktien
PLC - Public Limited Company

(a)
To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors.
(b)
Non-income producing security.
(c)
Security is exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may only be resold in transactions exempt from registration to qualified institutional investors. As of December 31, 2024, the value of these securities total $134,283 or 3.3% of the Fund’s net assets.
(d)
The rate shown represents the 7-day annualized effective yield as of December 31, 2024.

Summary of Fair Value Disclosure as of December 31, 2024 (Unaudited)
 
Amplify Weight Loss Drug & Treatment ETF has adopted authoritative fair value accounting standards which establish an authoritative definition of fair value and set out a hierarchy for measuring fair value. These standards require additional disclosures about the various inputs and valuation techniques used to develop the measurements of fair value, a discussion of changes in valuation techniques and related inputs during the period, and expanded disclosure of valuation levels for major security types. These inputs are summarized in the three broad levels listed below. The inputs or methodology used for valuing securities are not an indication of the risk associated with investing in those securities.
 
Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the Fund has the ability to access.
 
Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
 
Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing the Fund’s own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.
 
The following is a summary of the fair valuation hierarchy of the Fund’s securities as of December 31, 2024:
 
   
Level 1
    
Level 2
    
Level 3
    
Total
  
Investments:
                        
  Common Stocks
  
$
4,006,105
    
$
–
    
$
–
    
$
4,006,105
  
  Money Market Funds
    
83,307
      
–
      
–
      
83,307
  
Total Investments
  
$
4,089,412
    
$
–
    
$
–
    
$
4,089,412
  
   
Refer to the Schedule of Investments for further disaggregation of investment categories.
  
   


Allocation of Portfolio Holdings by Country as of December 31, 2024
  
(% of Net Assets)
  
United States
  
$
1,977,451
      
48.4
%
Denmark
    
645,327
      
15.9
  
Japan
    
518,150
      
12.8
  
Switzerland
    
223,255
      
5.5
  
Israel
    
195,715
      
4.8
  
United Kingdom
    
193,743
      
4.8
  
Germany
    
166,085
      
4.1
  
China
    
134,283
      
3.3
  
South Korea
    
22,674
      
0.6
  
Hong Kong
    
12,729
      
0.3
  
Liabilities in Excess of Other Assets
    
(21,280
)
    
(0.5
)
   
$
4,068,132
      
100.0
%